The Advisory Committee on Immunization Practices (ACIP) has approved the recommended immunization schedule for adults 19 years or older in the US. Changes in the 2016 adult immunization schedule from the 2015 schedule include the following new ACIP recommendations:

• Interval change for 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) was changed from 6 to 12 months to at least 1 year for adults aged ≥65 years who do not have immunocompromising conditions, anatomical or functional asplenia, cerebrospinal fluid leaks, or cochlear implants. The interval for adults aged ≥19 years with any of these conditions is at least 8 weeks.

• Serogroup B meningococcal (MenB) vaccine series should be administered to certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease.

• MenB vaccine series may be administered to adolescents and young adults aged 16 through 23 years (preferred age is 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease.

• Nine-valent human papillomavirus (HPV) vaccine (9vHPV) has been added to the schedule and can be used for routine vaccination of females and males against HPV.

Citation: Kim DK, Bridges CB, Harriman KH. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older — United States, 2016. MMWR Morb Mortal Wkly Rep 2016;65:1-3. doi: http://dx.doi.org/10.15585/mmwr.mm6504a5er.